Exenatide significantly improved 24-hour average glucose compared to sitagliptin in patients with type 2 diabetes

被引：0
|
作者：
Shenouda, S. K. [1 ]
Holcombe, J. H. [2 ]
Heilmann, C. R.
机构：
[1] Eli Lilly & Co, Global Med Commun, Indianapolis, IN 46285 USA
[2] Lilly USA LLC, Indianapolis, IN USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
831
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
    Maureen J. Lage
    Rosalind Fabunmi
    Kristina S. Boye
    Derek A. Misurski
    Advances in Therapy, 2009, 26 : 217 - 229
  • [22] Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study
    Schwartz, Sherwyn L.
    Ratner, Robert E.
    Kim, Dennis D.
    Qu, Yongming
    Fechner, Linda L.
    Lenox, Sheila M.
    Holcombe, John H.
    CLINICAL THERAPEUTICS, 2008, 30 (05) : 858 - 867
  • [23] Differences in the Effect of Sitagliptin on 24-Hour Glycemic Variations in Japanese Type 2 Diabetic Patients Receiving or Not Receiving Sulfonylureas as Assessed by Continuous Glucose Monitoring (CGM)
    Matsuura, Kenichi
    Mori, Yutaka
    Taniguchi, Yukiko
    Sezaki, Kazunori
    Yokoyama, Junichi
    Utsunomiya, Kazunori
    DIABETES, 2011, 60 : A601 - A601
  • [24] Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
    Lage, Maureen J.
    Fabunmi, Rosalind
    Boye, Kristina S.
    Misurski, Derek A.
    ADVANCES IN THERAPY, 2009, 26 (02) : 217 - 229
  • [25] Sitagliptin, a DPP-4 inhibitor, administered once- or twice-daily, provides improvement throughout 24-hour glucose control in Japanese patients with type 2 diabetes mellitus
    Nonaka, K.
    Tsubouchi, H.
    Okuyama, K.
    Fukao, Y.
    Stein, P. P.
    DIABETOLOGIA, 2007, 50 : S365 - S366
  • [26] 24-Hour Glycemic Variations in Drug-Naive Patients with Type 2 Diabetes: A Continuous Glucose Monitoring (CGM)-Based Study
    Ando, Kiyotaka
    Nishimura, Rimei
    Tsujino, Daisuke
    Seo, Chiaki
    Utsunomiya, Kazunori
    PLOS ONE, 2013, 8 (07):
  • [27] Effectiveness and Safety of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, compared with Sitagliptin in Patients with Type 2 Diabetes
    Brix, Johanna
    Gross, Jorge
    Yee, Mao Fu J.
    Kawaguchi, M.
    Canovatchel, W.
    Meininger, Gary
    Schernthaner, Guntram
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 : 20 - 20
  • [28] The Effect of Disease Severity on 24-Hour Urine Parameters in Kidney Stone Patients With Type 2 Diabetes
    Fram, Ethan B.
    Moazami, Saman
    Stern, Joshua M.
    UROLOGY, 2016, 87 : 52 - 59
  • [29] Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial
    Henry, Robert R.
    Strange, Poul
    Zhou, Rong
    Pettus, Jeremy
    Shi, Leon
    Zhuplatov, Sergey B.
    Mansfield, Traci
    Klein, David
    Katz, Arie
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (11) : 715 - 724
  • [30] 24-hour blood pressure monitoring and renal function in patients with type 1 diabetes
    Korzeniewska-Dyl, Irmina
    Walczak, Konrad
    Baranski, Michal
    Szadkowska, Agnieszka
    Madej, Anna
    Moczulski, Dariusz
    CLINICAL DIABETOLOGY, 2015, 4 (03): : 91 - 97
12345